Noul Co., Ltd.

B-10F, 338, Gwanggyojungang-ro, Suji-gu
Yongin-si,  Kyonggi-do  16942

Korea (South)
https://www.noul.com

• Booth: 4637

Noul is a biotech startup focused on improving access to modern, more accurate and eco-friendly diagnostic blood tests through its miLab testing platform. miLab is a compact, automated, all-in-one point-of-care diagnostics device which perfectly replicates the gold standard blood testing method and makes it possible for accurate, morphology-based blood tests to be conducted without water, without using earth-damaging chemicals, and without the traditional clinical lab and skilled technicians.

 Press Releases

• AI Diagnostic Platform Company Noul, unveils the result of Malaria study in (Jul 23, 2024)
  • Reaffirming innovation as an AI-based digital microscope while presenting new malaria data at the annual meeting of the ASTMH 2023

  • Noul’s ‘miLab™’ showed significantly higher sensitivity than that of microscopy in health centers

• On-Device AI Healthcare Company Noul Becomes an Official Member of Swiss Ma (Jul 23, 2024)
  • Obtain a membership in recognition of innovation in malaria diagnostic solution
  • Strengthen global leadership in malaria diagnosis based on European subsidiary

   

  (Yongin, Korea) February 9, 2023 – Noul Co., Ltd., (376930.KR), an On-Device AI healthcare company, announced that its European subsidiary (noul GmbH) has become an official member of the Swiss Malaria Group, a Swiss public, private, academic & civil society leadership network for a malaria-free world.

• Noul, a top On-Device AI healthcare company, joins CancerX, a cancer-fighti (Jul 23, 2024)

  As part of the Cancer Moonshot initiative announced at the White House, noul is delighted to announce its groundbreaking participation as a leading On-Device AI healthcare company in the private-public partnership, CancerX. Congratulations on noul’s efforts to take a step closer to global cancer conquest! 

   

  CancerX was announced in February 2023 as part of The White House’s reignited national Cancer Moonshot initiative. As a public-private partnership co-hosted by the U.S. government, Moffitt Cancer Center, the Digital Medicine Society (DiMe), and others, noul actively participated in this vital innovation, showcasing crucial technologies and products to combat cancer.

• On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studi (Jul 23, 2024)
  • miLab showed almost equivalent to WHO-certified first-degree microscopy experts: Sensitivity of 94.4%, Specificity of 98.1%
  • African authority on malaria diagnosis said “miLab is a potential game changer in accelerating access to parasitological confirmation”

   

  (Yongin, Korea) April 25, 2024 – Noul Co., Ltd., (376930.KR), an On-Device AI healthcare company, announced that the results of a clinical performance study of its malaria diagnostic solution showed a sensitivity of 94.4%, and a specificity of 98.1%, which is almost equivalent to WHO-certified first-degree microscopy experts.

• Noul Participates in a Malaria Project Initiated by U.S. CDC with Kenya Med (Jul 23, 2024)
  • Gain attention as an alternative technology to the malaria HRP-2/3 gene deletion problem in Africa
  • Prepare a bridgehead to enter the U.S. market by securing a credible reference

  June 17, 2024 – On-Device AI healthcare company, Noul, announced that it will jointly participate in a malaria diagnosis project initiated by U.S. Centers for Disease Control and Prevention (CDC) with the Kenya Medical Research Institute (KEMRI).